TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CrescNet - Computer-guided, Population-based Surveillance System for Growth Disorders
Brief Summary: CrescNet is a network of primary care physicians and pediatricians (n=219) and endocrinological treatment centers (n=33), established in Leipzig in 1998, whose aim is to improve the early detection of growth disorders. Secondary to this clinical aim, epidemiological analyses, for example on secular trends of growth data of children, are performed.


Options:
A: N/A
B: Arm Label: Bariatric surgery; Type: EXPERIMENTAL; Interventions: Procedure: Laparoscopic Roux-en-Y gastric bypass | Arm Label: Intense conservative treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intense conservative treatment | Intervention Type: PROCEDURE; Name: Laparoscopic Roux-en-Y gastric bypass; Assigned to Arm(s): Bariatric surgery | Intervention Type: PROCEDURE; Name: Intense conservative treatment; Assigned to Arm(s): Intense conservative treatment
C: Arm Label: Bariatric surgery; Type: OTHER; Interventions: Procedure: Bariatric surgery | Arm Label: Controls; Type: OTHER; Interventions: Other: Usual care | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Bariatric surgery | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Controls
D: Arm Label: g-Cath EZ Treatment Group; Type: EXPERIMENTAL; Interventions: Device: g-CathTM EZ Suture Anchor Delivery Catheter | Arm Label: Diet and exercise Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet and Exercise Control Group | Intervention Type: DEVICE; Name: g-CathTM EZ Suture Anchor Delivery Catheter; Assigned to Arm(s): g-Cath EZ Treatment Group | Intervention Type: OTHER; Name: Diet and Exercise Control Group; Assigned to Arm(s): Diet and exercise Control Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Renal and Vascular Endstage Disease Intervention Trial
Brief Summary: The Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) was designed to determine whether intervention with the angiotensin-converting enzyme (ACE) inhibitor fosinopril and/or the hydroxymethylglutaryl coenzyme A reductase inhibitor pravastatin reduced cardiovascular and renal events in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria.


Options:
A: Arm Label: Fosinopril + Pravastatin; Type: EXPERIMENTAL; Interventions: Drug: Fosinopril, Drug: Pravastatin | Arm Label: Fosinopril + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fosinopril, Drug: Pravastatin Placebo | Arm Label: Pravastatin + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin, Drug: Fosinopril Placebo | Arm Label: Double Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fosinopril Placebo, Drug: Pravastatin Placebo | Intervention Type: DRUG; Name: Fosinopril; Assigned to Arm(s): Fosinopril + Placebo, Fosinopril + Pravastatin | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Fosinopril + Pravastatin, Pravastatin + Placebo | Intervention Type: DRUG; Name: Fosinopril Placebo; Assigned to Arm(s): Double Placebo, Pravastatin + Placebo | Intervention Type: DRUG; Name: Pravastatin Placebo; Assigned to Arm(s): Double Placebo, Fosinopril + Placebo
B: Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
D: Arm Label: Pitavastatin 4 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 40 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 4 mg QD | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin 40 mg QD

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of PRO-CTCAE by Patients Receiving Immunotherapy for the Treatment of Malignant Melanoma
Brief Summary: This study evaluates if melanoma patients who report their side effects to immunotherapy weekly by the use of ePRO-CTCAE will experience an overall reduction of grade 3 and 4 events with 50% compared to routine monitoring carried out every 3 weeks.


Options:
A: Arm Label: FLARE Intervention Group; Type: OTHER; Interventions: Other: FLARE Intervention Group | Arm Label: Standard of Care (SOC) Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: FLARE Intervention Group; Assigned to Arm(s): FLARE Intervention Group
B: Arm Label: Structured patient visits; Type: OTHER; Interventions: Behavioral: Structured patient-centered follow up of depression | Arm Label: Treatment as usual; Type: OTHER; Interventions: Behavioral: Structured patient-centered follow up of depression | Intervention Type: BEHAVIORAL; Name: Structured patient-centered follow up of depression; Assigned to Arm(s): Structured patient visits, Treatment as usual
C: Arm Label: PRO-based follow-up; Type: EXPERIMENTAL; Interventions: Behavioral: PRO-based follow-up | Arm Label: PRO-based telephone consultations; Type: EXPERIMENTAL; Interventions: Behavioral: PRO-based telephone consultation | Arm Label: Usual outpatient follow-up visits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PRO-based follow-up; Assigned to Arm(s): PRO-based follow-up | Intervention Type: BEHAVIORAL; Name: PRO-based telephone consultation; Assigned to Arm(s): PRO-based telephone consultations
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Device: Tablet: Samsung Galaxy Tab A | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tablet: Samsung Galaxy Tab A; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A NORwegian Multicentre Randomised Controlled Trial Assessing the Effectiveness of Tailoring Infliximab Treatment by Therapeutic DRUg Monitoring - The NOR-DRUM Study
Brief Summary: Infliximab and other TNF-inhibitors have revolutionised the treatment of several immunological inflammatory diseases. Still, more than half of the patients either do not respond sufficiently to infliximab therapy or loose efficacy over time. The large individual variation in the serum drug concentrations on standard doses and the development of anti-drug antibodies are thought to be main reasons for these treatment failures. An individualised treatment strategy based on systematic assessments of serum drug concentrations, therapeutic drug monitoring, has been proposed as a clinical tool to optimise efficacy of infliximab treatment. Therapeutic drug monitoring seems reasonable both from a clinical and an economical point of view, but the effectiveness of this treatment strategy still remain to be shown. The NOR-DRUM study is planned as a national, randomised controlled multicentre trial in two parts aiming to assess the effectiveness of therapeutic drug monitoring in order to achieve remission in patients with immunological inflammatory diseases starting infliximab treatment (part A) and in order to maintain disease control in patients on maintenance infliximab treatment (part B). The results of the NOR-DRUM study will hopefully contribute to an implementation of a personalised medicine approach to treatment with infliximab and other biological drugs.


Options:
A: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
B: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
C: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A NORwegian Multicentre Randomised Controlled Trial Assessing the Effectiveness of Tailoring Infliximab Treatment by Therapeutic DRUg Monitoring - The NOR-DRUM Study
Brief Summary: Infliximab and other TNF-inhibitors have revolutionised the treatment of several immunological inflammatory diseases. Still, more than half of the patients either do not respond sufficiently to infliximab therapy or loose efficacy over time. The large individual variation in the serum drug concentrations on standard doses and the development of anti-drug antibodies are thought to be main reasons for these treatment failures. An individualised treatment strategy based on systematic assessments of serum drug concentrations, therapeutic drug monitoring, has been proposed as a clinical tool to optimise efficacy of infliximab treatment. Therapeutic drug monitoring seems reasonable both from a clinical and an economical point of view, but the effectiveness of this treatment strategy still remain to be shown. The NOR-DRUM study is planned as a national, randomised controlled multicentre trial in two parts aiming to assess the effectiveness of therapeutic drug monitoring in order to achieve remission in patients with immunological inflammatory diseases starting infliximab treatment (part A) and in order to maintain disease control in patients on maintenance infliximab treatment (part B). The results of the NOR-DRUM study will hopefully contribute to an implementation of a personalised medicine approach to treatment with infliximab and other biological drugs.


Options:
A: Arm Label: proactive infliximab optimization; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Arm Label: standard of care infliximab dosing; Type: EXPERIMENTAL; Interventions: Drug: Infliximab | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): proactive infliximab optimization, standard of care infliximab dosing
B: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Developing and Testing Implementation Strategies for Evidence-Based Obesity Prevention in Childcare
Brief Summary: Investigators will pilot test the impact of an enhanced implementation strategy on implementation and child health outcomes using continuous formative evaluation. Investigators will test the hypothesis that better fidelity to the implementation strategy (WISE) is positively related to child outcomes (e.g., child fruit and vegetable intake, BMI).


Options:
A: Arm Label: CHAMP group; Type: EXPERIMENTAL; Interventions: Behavioral: CHAMP | Arm Label: CHAMP+ group; Type: EXPERIMENTAL; Interventions: Behavioral: CHAMP, Behavioral: CHAMP+ | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHAMP; Assigned to Arm(s): CHAMP group, CHAMP+ group | Intervention Type: BEHAVIORAL; Name: CHAMP+; Assigned to Arm(s): CHAMP+ group
B: Arm Label: Center-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Center-based Intervention | Arm Label: Center-and-home-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based Intervention | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: Center-based Intervention; Assigned to Arm(s): Center-based intervention | Intervention Type: BEHAVIORAL; Name: Home-based Intervention; Assigned to Arm(s): Center-and-home-based intervention | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active Control
C: Arm Label: Basic WISE strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WISE (We Inspire Smart Eating) | Arm Label: Enhanced WISE strategy; Type: EXPERIMENTAL; Interventions: Behavioral: WISE (We Inspire Smart Eating) | Intervention Type: BEHAVIORAL; Name: WISE (We Inspire Smart Eating); Assigned to Arm(s): Basic WISE strategy, Enhanced WISE strategy
D: Arm Label: parent intervention plus gym lessons; Type: EXPERIMENTAL; Interventions: Behavioral: parent-focused intervention, Behavioral: twice weekly gym lessons | Arm Label: gym lessons only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: twice weekly gym lessons | Intervention Type: BEHAVIORAL; Name: parent-focused intervention; Assigned to Arm(s): parent intervention plus gym lessons | Intervention Type: BEHAVIORAL; Name: twice weekly gym lessons; Assigned to Arm(s): gym lessons only, parent intervention plus gym lessons

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Developing and Testing Implementation Strategies for Evidence-Based Obesity Prevention in Childcare
Brief Summary: Investigators will pilot test the impact of an enhanced implementation strategy on implementation and child health outcomes using continuous formative evaluation. Investigators will test the hypothesis that better fidelity to the implementation strategy (WISE) is positively related to child outcomes (e.g., child fruit and vegetable intake, BMI).


Options:
A: Arm Label: Program SI! educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Program SI! educational intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Program SI! educational intervention; Assigned to Arm(s): Program SI! educational intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Parents Connect for Healthy Living (PConnect), Behavioral: Enhanced Nutrition Support, Behavioral: Media Resources | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Parents Connect for Healthy Living (PConnect); Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Nutrition Support; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Media Resources; Assigned to Arm(s): Intervention
C: Arm Label: Basic WISE strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WISE (We Inspire Smart Eating) | Arm Label: Enhanced WISE strategy; Type: EXPERIMENTAL; Interventions: Behavioral: WISE (We Inspire Smart Eating) | Intervention Type: BEHAVIORAL; Name: WISE (We Inspire Smart Eating); Assigned to Arm(s): Basic WISE strategy, Enhanced WISE strategy
D: Arm Label: CHild Inhibitory Control Play (CHIC) Play; Type: EXPERIMENTAL; Interventions: Behavioral: CHild Inhibitory Control (CHIC) Play | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention control | Intervention Type: BEHAVIORAL; Name: CHild Inhibitory Control (CHIC) Play; Assigned to Arm(s): CHild Inhibitory Control Play (CHIC) Play | Intervention Type: BEHAVIORAL; Name: Attention control; Assigned to Arm(s): Attention control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Developing and Testing Implementation Strategies for Evidence-Based Obesity Prevention in Childcare
Brief Summary: Investigators will pilot test the impact of an enhanced implementation strategy on implementation and child health outcomes using continuous formative evaluation. Investigators will test the hypothesis that better fidelity to the implementation strategy (WISE) is positively related to child outcomes (e.g., child fruit and vegetable intake, BMI).


Options:
A: Arm Label: CHAMP group; Type: EXPERIMENTAL; Interventions: Behavioral: CHAMP | Arm Label: CHAMP+ group; Type: EXPERIMENTAL; Interventions: Behavioral: CHAMP, Behavioral: CHAMP+ | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHAMP; Assigned to Arm(s): CHAMP group, CHAMP+ group | Intervention Type: BEHAVIORAL; Name: CHAMP+; Assigned to Arm(s): CHAMP+ group
B: Arm Label: Standard Palatability and Standard Portion Size; Type: EXPERIMENTAL; Interventions: Other: Plain Vegetables Served in 100% Portion Size | Arm Label: Standard Palatability and Larger Portion Size; Type: EXPERIMENTAL; Interventions: Other: Plain Vegetables Served in 200% Portion Size | Arm Label: Enhanced Palatability and Standard Portion Size; Type: EXPERIMENTAL; Interventions: Other: Enhanced Vegetables Served in 100% Portion Size | Arm Label: Enhanced Palatability and Larger Portion Size; Type: EXPERIMENTAL; Interventions: Other: Enhanced Vegetables Served in 200% Portion Size | Intervention Type: OTHER; Name: Plain Vegetables Served in 100% Portion Size; Assigned to Arm(s): Standard Palatability and Standard Portion Size | Intervention Type: OTHER; Name: Plain Vegetables Served in 200% Portion Size; Assigned to Arm(s): Standard Palatability and Larger Portion Size | Intervention Type: OTHER; Name: Enhanced Vegetables Served in 100% Portion Size; Assigned to Arm(s): Enhanced Palatability and Standard Portion Size | Intervention Type: OTHER; Name: Enhanced Vegetables Served in 200% Portion Size; Assigned to Arm(s): Enhanced Palatability and Larger Portion Size
C: Arm Label: Basic WISE strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WISE (We Inspire Smart Eating) | Arm Label: Enhanced WISE strategy; Type: EXPERIMENTAL; Interventions: Behavioral: WISE (We Inspire Smart Eating) | Intervention Type: BEHAVIORAL; Name: WISE (We Inspire Smart Eating); Assigned to Arm(s): Basic WISE strategy, Enhanced WISE strategy
D: Arm Label: Healthy Lifestyles Group; Type: EXPERIMENTAL; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Arm Label: Healthy Business Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Intervention Type: BEHAVIORAL; Name: Keys to Healthy Family Child Care Homes; Assigned to Arm(s): Healthy Business Group, Healthy Lifestyles Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Standard of Care in Subjects With Previously Untreated and Advanced (Unresectable or Metastatic) Non-clear Cell Renal Cell Carcinoma (nccRCC)
Brief Summary: SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab (BMS-936558) combined with Ipilimumab vs standard of care in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma (nccRCC).


Options:
A: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib
B: Arm Label: Ipilimumab plus nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab plus nivolumab | Arm Label: Standard of Care therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Therapy | Intervention Type: DRUG; Name: Ipilimumab plus nivolumab; Assigned to Arm(s): Ipilimumab plus nivolumab | Intervention Type: DRUG; Name: Standard Therapy; Assigned to Arm(s): Standard of Care therapy
C: Arm Label: Tivozanib hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib hydrochloride | Arm Label: Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Tivozanib hydrochloride; Assigned to Arm(s): Tivozanib hydrochloride | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Sorafenib
D: Arm Label: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm B: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm B: Sunitinib 50 mg

Answer: B